First Wave BioPharma announces phase 2 trial

2 years ago

by David Miller

947 Views

Written by David Miller

Clinical-stage biopharmaceutical company, First Wave BioPharma, has announced that it is planning to begin its phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase to treat exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients.

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!